Provides a broad overview of the immunological microenvironment in any given tissue Covers key myeloid and lymphoid populations, and activation marker expression in these subsets. - CD4+ T cells - CD8+ T cells - NK cells - B cells - Monocytic MDSCs (Mo-MDSCs)/classical monocytes, - Polymorphnuclear MDSCs (PMN-MDSCs)/neutrophils, - Classical dendritic cell 1 and 2 - Tumor-associated macrophages/macrophages Markers: CD45, CD3, CD4, CD8, CD11b, CD11c, CD19, CD64, CD68, CD69*, CD86*, CD206*, Ly6c, Ly6g, MHCII, NKp46, viability dye (* = changeable markers). Includes flexibility by having three changeable markers to decipher your specific focus. Examples of focus could include - Evaluation of enhancement of antigen presentation using e.g. CD80, CD86, IL-12, MHC II and MHC I bound epitopes (in a few models) - Evaluation of suppressive markers such as IL-10 and PD-L1 - Evaluation of macrophage polarization markers such as CD80, CD86, CD163, CD206 and PD-L1 - Evaluation of cancer antigen specificity using MHC multimers - Evaluation of regulatory T cells using FoxP3 - Evaluation of T cell phenotypes using e.g. CD44, CD62L, CTLA4, PD-1, Granzyme B and IFNγ (A) Infiltration of evaluated immune subsets (B) Viability and overall immune infiltration (C) Tumor-associated macrophage (TAM) polarization into M1 and M2 subsets based on CD86 (M1 marker) and CD206 (M2 marker). The M1 TAM phenotype supports T cells and are regarded as anti-tumorigenic while the M2 TAM phenotype suppresses T cells and are regarded as pro-tumorigenic. (D) Gating strategy
